Intracellular PD Modelling (PDi) for the Prediction of Clinical Activity of Increased Rifampicin Dosing. (2019)
Attributed to:
Understanding pharmacokinetic - pharmacodynamic determinants of outcome to inform dose optimisation for non-MDR TB re-treatment patients in Vietnam
funded by
Newton Fund
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.3390/pharmaceutics11060278
PubMed Identifier: 31200534
Publication URI: http://europepmc.org/abstract/MED/31200534
Type: Journal Article/Review
Volume: 11
Parent Publication: Pharmaceutics
Issue: 6
ISSN: 1999-4923